Dr. Marina Shcherba, DO

Dr. Shcherba practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Shcherba's NPI, 1902064975, was assigned on May 27, 2008. Dr. Shcherba graduated from Rowan University School of Osteopathic Medicine in 2007. Dr. Shcherba holds New York license 255574.

Dr. Shcherba's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Shcherba's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dr. Shcherba is also affiliated with Riverview Medical Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Shcherba to 3 more group practices and clinics, 3 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shcherba practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shcherba's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Shcherba is licensed in New York.

CMS data shows 906 Medicare services from Dr. Shcherba across 3 procedure codes in 2024, all of them office visits, for 308 Medicare patients. Medicare paid $78,782 for them. Every service was in an office.

CMS counts 308 Medicare patients who saw Dr. Shcherba in 2024. The largest group is 65 to 74, with 145 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shcherba's median patient age at 73, with 47% women.

In 2024, Dr. Shcherba wrote 585 Medicare Part D claims for 150 patients. 79% of them were for generic drugs. CMS names the drug for 398 of them, across 15 drugs with 11 or more claims each, at $347,461 in total drug cost. In 2023, CMS named 212 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Shcherba for performance year 2024, reported as part of a group. Dr. Shcherba accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shcherba as offering telehealth.

Dmand AI links 16 papers to Dr. Shcherba, published from 2013 to 2025. 2013 was the busiest year, with 2. The most frequent topics are Neoadjuvant Therapy, Adenocarcinoma and Antibodies, Monoclonal, Humanized. Dr. Shcherba has published most often in N Engl J Med. Dr. Shcherba's most frequent co-authors are Ping Gu, MD, Yelena Y. Janjigian, MD and Steven Maron, MD.

Dmand AI links Dr. Shcherba to 1 clinical trial.

CMS Open Payments shows 3 general payments to Dr. Shcherba from 3 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 100% of the total. Celgene Corporation paid the most, $95.

Dr. Shcherba graduated from Rowan University School of Osteopathic Medicine in 2007.